» Articles » PMID: 35957902

Metabolic Reprogramming Helps to Define Different Metastatic Tropisms in Colorectal Cancer

Abstract

Approximately 25% of colorectal cancer (CRC) patients experience systemic metastases, with the most frequent target organs being the liver and lung. Metabolic reprogramming has been recognized as one of the hallmarks of cancer. Here, metabolic and functional differences between two CRC cells with different metastatic organotropisms (metastatic KM12SM CRC cells to the liver and KM12L4a to the lung when injected in the spleen and in the tail vein of mice) were analysed in comparison to their parental non-metastatic isogenic KM12C cells, for a subsequent investigation of identified metabolic targets in CRC patients. Meta-analysis from proteomic and transcriptomic data deposited in databases, qPCR, WB, cell-based assays, and experiments were used to survey for metabolic alterations contributing to their different organotropism and for the subsequent analysis of identified metabolic markers in CRC patients. Although no changes in cell proliferation were observed between metastatic cells, KM12SM cells were highly dependent on oxidative phosphorylation at mitochondria, whereas KM12L4a cells were characterized by being more energetically efficient with lower basal respiration levels and a better redox management. Lipid metabolism-related targets were found altered in both cell lines, including , , , , , and , which were also associated with the prognosis of CRC patients. Moreover, CD36 association with lung metastatic tropism of CRC cells was validated Altogether, our results suggest that , , , , , , and metabolic targets are associated with CRC metastatic tropism to the liver or lung. These features exemplify specific metabolic adaptations for invasive cancer cells which stem at the primary tumour.

Citing Articles

From Crypts to Cancer: A Holistic Perspective on Colorectal Carcinogenesis and Therapeutic Strategies.

Gharib E, Robichaud G Int J Mol Sci. 2024; 25(17).

PMID: 39273409 PMC: 11395697. DOI: 10.3390/ijms25179463.


Fatty acid metabolism-related enzymes in colorectal cancer metastasis: from biological function to molecular mechanism.

Li B, Mi J, Yuan Q Cell Death Discov. 2024; 10(1):350.

PMID: 39103344 PMC: 11300464. DOI: 10.1038/s41420-024-02126-9.


Novel bioactive extract from yarrow obtained by the supercritical antisolvent-assisted technique inhibits lipid metabolism in colorectal cancer.

Gomez de Cedron M, Siles-Sanchez M, Martin-Hernandez D, Jaime L, Santoyo S, Ramirez de Molina A Front Bioeng Biotechnol. 2024; 12:1256190.

PMID: 38576446 PMC: 10991822. DOI: 10.3389/fbioe.2024.1256190.


Lipids as mediators of cancer progression and metastasis.

Vogel F, Chaves-Filho A, Schulze A Nat Cancer. 2024; 5(1):16-29.

PMID: 38273023 DOI: 10.1038/s43018-023-00702-z.


Low serum apolipoprotein A1 level predicts poor prognosis of patients with diffuse large B-cell lymphoma in the real world: a retrospective study.

Huang X, Wang Y, Huang Z, Chen X, Lin Q, Huang H BMC Cancer. 2024; 24(1):62.

PMID: 38212711 PMC: 10785512. DOI: 10.1186/s12885-024-11818-5.


References
1.
Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

2.
Sanchez-Martinez R, Cruz-Gil S, Gomez de Cedron M, Alvarez-Fernandez M, Vargas T, Molina S . A link between lipid metabolism and epithelial-mesenchymal transition provides a target for colon cancer therapy. Oncotarget. 2015; 6(36):38719-36. PMC: 4770732. DOI: 10.18632/oncotarget.5340. View

3.
Sun S . N-acetylcysteine, reactive oxygen species and beyond. Cancer Biol Ther. 2009; 9(2):109-10. PMC: 2854288. DOI: 10.4161/cbt.9.2.10583. View

4.
Radisky D, Levy D, Littlepage L, Liu H, Nelson C, Fata J . Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability. Nature. 2005; 436(7047):123-7. PMC: 2784913. DOI: 10.1038/nature03688. View

5.
Huang J, Li L, Lian J, Schauer S, Vesely P, Kratky D . Tumor-Induced Hyperlipidemia Contributes to Tumor Growth. Cell Rep. 2016; 15(2):336-48. PMC: 4984953. DOI: 10.1016/j.celrep.2016.03.020. View